Cadence files NDA for Acetavance

Cadence Pharmaceuticals has submitted an NDA for Acetavance (intravenous acetaminophen), a potential treatment of acute pain and fever in adults and children. If approved, Acetavance would become the first new IV analgesic approved in the U.S. in more than 20 years, as well as the only approved intravenous agent for the fever. Report